CDK4

CDK4
Structures disponibles
PDB	Recherche d'orthologue: PDBe RCSB
Identifiants PDB
	2W96, 2W99, 2W9F, 2W9Z, 3G33, 5FWL, 5FWM, 5FWK
Identifiants
Aliases	CDK4
IDs externes	OMIM: 123829 MGI: 88357 HomoloGene: 55429 GeneCards: CDK4
Position du gène (Homme)
Chr.	Chromosome 12 humain
Fin	57,756,013 bp
Expression génétique
	Fortement exprimé dans
	éminence ganglionnaire; ; stromal cell of endometrium; ; right adrenal gland; ; muscle lisse; ; left adrenal gland; ; left uterine tube; ; endocol; ; Myomètre; ; anté-hypophyse; ; pancréas;
	n/a
	Plus de données d'expression de référence
	Plus de données d'expression de référence
Gene Ontology
Fonction moléculaire	activité de transférase; liaison nucléotide; protein kinase activity; activité kinase; protein serine/threonine kinase activity; cyclin-dependent protein serine/threonine kinase regulator activity; liaison protéique; liaison ATP; cyclin binding; cyclin-dependent protein serine/threonine kinase activity; liaison de complexe macromoléculaire;
Composant cellulaire	cytoplasme; cytosol; cyclin-dependent protein kinase holoenzyme complex; membrane nucléaire; membrane; transcription regulator complex; bicellular tight junction; nucléoplasme; nucléole; perinuclear region of cytoplasm; chromatine; noyau; cyclin D2-CDK4 complex; complexe macromoléculaire;
Processus biologique	phosphorylation; response to testosterone; positive regulation of fibroblast proliferation; response to hyperoxia; positive regulation of translation; régulation du cycle cellulaire; division cellulaire; phosphorylation des protéines; lens development in camera-type eye; regulation of cell population proliferation; response to lead ion; rythme circadien; animal organ regeneration; positive regulation of cell population proliferation; positive regulation of cell size; positive regulation of apoptotic process; régulation de l'expression des gènes; cycle cellulaire; positive regulation of G2/M transition of mitotic cell cycle; réponse à une substance toxique; positive regulation of cell cycle; transduction de signal; développent d'un organisme multicellulaire; response to organic substance; cellular response to insulin stimulus; regulation of multicellular organism growth; regulation of insulin receptor signaling pathway; regulation of lipid biosynthetic process; regulation of lipid catabolic process; adipose tissue development; cellular response to lipopolysaccharide; cellular response to interleukin-4; cellular response to phorbol 13-acetate 12-myristate; cellular response to ionomycin; transcription initiation from RNA polymerase II promoter; G1/S transition of mitotic cell cycle; regulation of cyclin-dependent protein serine/threonine kinase activity; negative regulation of G1/S transition of mitotic cell cycle;
	Sources:Amigo / QuickGO
Orthologues
	1019
	12567
	ENSG00000135446
	n/a
	P11802
	P30285
	NM_052984; NM_000075
	NM_009870; NM_001355005
	NP_000066
	NP_034000; NP_001341934
	Wikidata
Voir/Editer Humain	Voir/Editer Souris

La CDK4 est une kinase dépendante des cyclines. Son gène est le CDK4 situé sur le chromosome 12 humain.

Fonction de Cdk4 modifier

Le complexe Cdk4-cycline D phosphoryle la pRB, engendrant un changement conformationnel la rendant inactif, libérant E2F et permettant à la cellule de progresser dans le cycle cellulaire.

En médecine modifier

Cette protéine joue un rôle dans la prolifération cellulaire, notamment dans les cancers^[4], constituant une cible thérapeutique. Le palbociclib^[5] et le ribociclib^[6] sont des inhibiteurs des CDK4 et CDK6 efficaces dans certains cancers du sein.

Notes et références modifier

↑ ^{a b et c} GRCh38: Ensembl release 89: ENSG00000135446 - Ensembl, May 2017
↑ « Publications PubMed pour l'Homme », sur National Center for Biotechnology Information, U.S. National Library of Medicine
↑ « Publications PubMed pour la Souris », sur National Center for Biotechnology Information, U.S. National Library of Medicine
↑ Hamilton E, Infante JR, Targeting CDK4/6 in patients with cancer, Cancer Treat Rev, 2016;45:129-138
↑ Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 2015;16:25-35
↑ Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N Engl J Med, 2016;375:1738-1748

[refGRCh38Ensembl-1] {a b et c} GRCh38: Ensembl release 89: ENSG00000135446 - Ensembl, May 2017

[2] « Publications PubMed pour l'Homme », sur National Center for Biotechnology Information, U.S. National Library of Medicine

[3] « Publications PubMed pour la Souris », sur National Center for Biotechnology Information, U.S. National Library of Medicine

[Hamilton_2016-4] Hamilton E, Infante JR, Targeting CDK4/6 in patients with cancer, Cancer Treat Rev, 2016;45:129-138

[Finn_2015-5] Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 2015;16:25-35

[Hortobagyi_2016-6] Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N Engl J Med, 2016;375:1738-1748

[1]

[2]

[3]

[4]

[5]

[6]